Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04710563

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

A research project capturing experiences of patients with critical limb threatening ischemia, with the ultimate goal of setting new standards for diagnosing, describing detailed patient-centered outcomes, and evaluating the variability in therapeutic approaches and their association with outcomes.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Yale New Haven Health

New Haven, Connecticut, 06510, United States

About this study

An estimated 8 million individuals in America are affected by peripheral arterial disease (PAD). One of its extreme expressions is Critical Limb Ischemia (CLI). It is one of the most severe vascular conditions associated with devastating outcomes, including poorly healing wounds, extreme pain, and a high amputation risk. It is also one of the deadliest conditions, with 6-month and 5-year mortality rates estimated to be 20 and >50%, respectively. To date, however, there is a paucity of prospective clinical evidence about the variability in patients' presentations, their management or their outcomes. Accordingly, little progress has been made in adequately staging the disease and to risk-stratify treatment approaches to patients' individual characteristics. What is desperately needed to advance the care and management of patients with CLI is a focused research effort to set new standards for diagnosing, describing detailed patient-centered outcomes, and evaluating the variability in therapeutic approaches and their association with outcomes. The specific aims of SCOPE-CLI are to generate new evidence on the clinical characteristics, treatment patterns and outcomes of patients with critical limb ischemia (CLI); to describe treatment patterns and variability across practices to identify gaps in delivering quality care; and to perform a series of analyses to examine the associations of patient and treatment characteristics with outcomes. The central objective of SCOPE-CLI is to systematically quantify patients' CLI-specific health status and clinical outcomes and to perform subgroup analyses as a function of different PAD treatments and patient characteristics.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All race/ethnicity categories, English speaking, men and women
  • Patient presents with current (within 30 days) Rutherford Class 4, 5, or 6
  • Age ≥18 years
  • Supported by any of the following diagnostic evidence:
  • Rutherford Classification 4 or ischemic rest pain and/or resting ankle pressure <50mmHg, flat or barely pulsatile ankle or metatarsal PVR or toe pressure <40mmHg
  • Rutherford Classification 5 or minor tissue loss; non-healing ulcer, focal gangrene with diffuse pedal ischemia resting ankle pressure <50mmHg ankle or metatarsal PVR flat or barely pulsatile or toe pressure <40mmHg
  • Rutherford Classification 6 or major tissue loss: extending above transmetatarsal level, functional foot no longer salvageable, resting ankle pressure <50mmHg ankle or metatarsal PVR flat or barely pulsatile or toe pressure <40mmHg
  • CLI related ICD 10 code (reason for admission or indication for procedure)
  • SPP < 50 mmHg
  • TCPO2 < 50 mmHg
  • Angiographic evidence no straight line to foot or greater than 70% stenosis in all 3 lower extremity arteries (AT, PT, peroneal)
  • ABI* ≤ 0.90
  • non-compressible ABI ≥ 1.40 AND TBI ≤ 0.70
  • TBI* ≤ 0.70

Exclusion criteria

  • Acute limb ischemia
  • Unable to provide written informed consent
  • Currently a prisoner (identified at time of enrollment)

Treatment and study plan

Primary outcomes

  1. Peripheral Artery Questionnaire (PAQ)

    Time frame: After enrollment and follow-up at month 1

    PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.

  2. Peripheral Artery Questionnaire (PAQ)

    Time frame: After enrollment and follow-up at month 2

    PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.

  3. Peripheral Artery Questionnaire (PAQ)

    Time frame: After enrollment and follow-up at month 6

    PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.

  4. Peripheral Artery Questionnaire (PAQ)

    Time frame: After enrollment and follow-up at month 12

    PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.

Secondary outcomes

  1. Major adverse limb events (MALE)

    Time frame: 6 months after enrollment

    Major adverse limb events include: major amputation above the level of the ankle joint, thrombolysis/thrombectomy or surgical bypass or graft revision, after diagnostic or interventional lower extremity angiography)

  2. Major adverse limb events (MALE)

    Time frame: 12 months after enrollment

    Major adverse limb events include: major amputation above the level of the ankle joint, thrombolysis/thrombectomy or surgical bypass or graft revision, after diagnostic or interventional lower extremity angiography)

  3. Major adverse limb events (MALE)

    Time frame: 5 years after enrollment

    Major adverse limb events include: major amputation above the level of the ankle joint, thrombolysis/thrombectomy or surgical bypass or graft revision, after diagnostic or interventional lower extremity angiography)

  4. Amputation Free Survival (AFS)

    Time frame: 6 months after enrollment

    AFS will be a measure of number of patients "free from death or above ankle amputation"

  5. Amputation Free Survival (AFS)

    Time frame: 12 months after enrollment

    AFS will be a measure of number of patients "free from death or above ankle amputation"

  6. Amputation Free Survival (AFS)

    Time frame: 5 years after enrollment

    AFS will be a measure of number of patients "free from death or above ankle amputation"

  7. Mortality - Death

    Time frame: 6 months after enrollment

    Vital status obtained from either medical records or social security death index will be assessed to account for number of patients who died

  8. Mortality - Death

    Time frame: 12 months after enrollment

    Vital status obtained from either medical records or social security death index will be assessed to account for number of patients who died

  9. Mortality - Death

    Time frame: 5 years after enrollment

    Vital status obtained from either medical records or social security death index will be assessed to account for number of patients who died

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Abbott
  • Baylor College of Medicine
  • Brown University
  • Columbia University
  • Emory University
  • Janssen Scientific Affairs, LLC
  • Oregon Health and Science University
  • Saint Luke's Health System
  • The Cleveland Clinic
  • University of California, Davis
  • University of Chicago
  • University of Minnesota
  • University of Southern California

Registry information

Official study title

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia

Acronym: SCOPE-CLI

Important dates

Study start
2021
Primary completion
2024
Study completion
2028
First posted
Jan 14, 2021
Registry last updated
Oct 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.